Everything you need to know about fda chief resigns after trump admin.
[ad_1]Earlier this month, The Wall Street Journal reported that Trump had called Makary over a weekend to scold him for not moving fast enough to authorize flavored vapes, particularly menthol, mango, and blueberry flavors from the Los Angeles manufacturer Glas. The FDA authorized those flavored products days later and issued a new policy that would make it easier to market flavored vapes.
Officials in the Trump administration also noted that Makary had angered anti-abortion activists, who accused him of slow-walking a safety review of mifepristone, a pill used for abortion and miscarriage treatment.
Officials also said Makary butted heads with other health officials and was seen as struggling to manage his agency. He reportedly made enemies among lobbyists for the biotech, tobacco, and pharmaceutical industries. Public health experts, meanwhile, criticized Makary for changes to the FDA’s vaccine reviews under his watch, which aligned with Health Secretary Robert F. Kennedy’s anti-vaccine agenda.
“He has offended almost everyone involved in FDA issues, which is not easy to do,” Diana Zuckerman, the president of the National Center for Health Research, told the Times.
According to Politico, which was the first to report Makary’s resignation, it was Kennedy—not Trump—who made the call on planning to fire Makary, though Trump had to agree.
[ad_2]
Source link
More on fda chief resigns after trump admin
Stay tuned for updates on fda chief resigns after trump admin as the story develops. Related: Mobile & Accessories.
Frequently Asked Questions
According to the article, he resigned after the Trump administration forced approval of fruity e-cigarettes, and Politico reported it was Health Secretary Robert F. Kennedy, not Trump, who made the call on planning to fire him.
The FDA authorized menthol, mango, and blueberry flavors from Los Angeles manufacturer Glas, days after Trump reportedly called Makary to scold him for not moving fast enough.
He angered anti-abortion activists accused of slow-walking a mifepristone safety review, butted heads with health officials, made enemies among biotech, tobacco and pharma lobbyists, and aligned FDA vaccine reviews with Kennedy's anti-vaccine agenda.
Diana Zuckerman, president of the National Center for Health Research, said he 'has offended almost everyone involved in FDA issues, which is not easy to do.'




